KYTHERA Biopharmaceuticals Acquired By Allergan For $2.1 Billion

Westlake Vilage-based KYTHERA Biopharmaceuticals, the developer of aesthetic medicine products, is being acquired by Allergan in a deal worth $2.1 billion, the two companies said this morning. Allergan said it will pay $75 per KYTHERA share, split between 80 percent in cash and 20 percent in Allergan shares. Kythera is focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The company's lead product is used to treat double chins.